Immunome director granted 9,897 stock options

Immunome Inc. director Sandra M. Swain received a grant of stock options covering 9,897 shares of common stock.

Rhea-AI Filing Summary

Immunome Inc. director Sandra M. Swain received a grant of stock options covering 9,897 shares of common stock. The options have an exercise price of $18.16 per share and expire on June 9, 2036.

The award vests in four equal quarterly installments starting on June 10, 2026, with additional vesting on the same day of each succeeding fiscal quarter until the one-year anniversary, as long as she continues serving with the company on each vesting date. Following this grant, she holds options for 9,897 shares directly.

Insider Trade Summary

Grant/Award: 9,897 shares

Grant/Award 1 txn

Insider SWAIN SANDRA M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)`	9,897	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy)` — 9,897 contracts (Direct)

Footnotes (1)

1. F1. The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

Key Figures

Options granted: 9,897 shares Exercise price: $18.16 per share Underlying shares: 9,897 shares +2 more

5 metrics

Options granted 9,897 shares Director stock option grant on June 10, 2026

Exercise price $18.16 per share Director stock option grant

Underlying shares 9,897 shares Common stock underlying the option award

Post-grant option holdings 9,897 shares Total options held following the reported transaction

Option expiration June 9, 2036 Expiration date of the director stock option

Key Terms

Director Stock Option, exercise price, vesting, expiration date, +1 more

5 terms

Director Stock Option financial

"Director Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price": "18.1600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests in four equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date": "2036-06-09T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title": "Common Stock""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immunome (IMNM) director Sandra Swain report in this Form 4?

Sandra M. Swain reported receiving a grant of stock options for 9,897 shares of Immunome common stock. These options are a form of equity compensation and do not represent an open-market purchase or sale of existing shares.

How many Immunome (IMNM) shares are covered by Sandra Swain’s stock options?

The option grant covers 9,897 shares of Immunome common stock. This number reflects the total underlying shares tied to the award and matches her total option holdings reported following the transaction.

What is the exercise price of Sandra Swain’s Immunome (IMNM) stock options?

The options have an exercise price of $18.16 per share. This is the fixed price at which she can purchase Immunome common stock if and when the options vest and she chooses to exercise them.

When do Sandra Swain’s Immunome (IMNM) stock options vest?

The options vest in four equal quarterly installments, beginning June 10, 2026. Additional installments vest on the same calendar day of each succeeding fiscal quarter over one year, subject to her continuous service with Immunome on each vesting date.

When do Sandra Swain’s Immunome (IMNM) stock options expire?

The reported options expire on June 9, 2036. After this expiration date, any unexercised portion of the award will lapse and can no longer be used to purchase Immunome common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SWAIN SANDRA M

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)`	$18.16	06/10/2026		A		9,897		(1)	06/09/2036	Common Stock	9,897	$0	9,897	D

Explanation of Responses:

1. The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

	/s/ Sandra Stoneman, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)